Your session is about to expire
← Back to Search
Neuromuscular Blocker
Neuromuscular blockade for Extracorporeal Membrane Oxygenation (PNEUMA Trial)
N/A
Waitlist Available
Led By Ewan Goligher, MD, PhD
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up assessed maintenance 24 hours phase
Awards & highlights
PNEUMA Trial Summary
This trial is testing a new way to help people with a severe lung disease who are using a machine to help them breathe.
Eligible Conditions
- Extracorporeal Membrane Oxygenation
- Neuromuscular Blockade
- Respiratory Insufficiency
PNEUMA Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ assessed maintenance 24 hours phase
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~assessed maintenance 24 hours phase
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Rate of patients achieving and maintaining targeted esophageal pressure swings
Secondary outcome measures
Rates of serious adverse events
PNEUMA Trial Design
1Treatment groups
Experimental Treatment
Group I: Partial NMBExperimental Treatment1 Intervention
Find a Location
Who is running the clinical trial?
University Health Network, TorontoLead Sponsor
1,475 Previous Clinical Trials
485,086 Total Patients Enrolled
Ewan Goligher, MD, PhDPrincipal InvestigatorUniversity Health Network, Toronto
7 Previous Clinical Trials
6,598 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger